<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>64 patients with extensive non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were treated with a modified MOPP scheme </plain></SENT>
<SENT sid="1" pm="."><plain>41 patients had stage IV disease </plain></SENT>
<SENT sid="2" pm="."><plain>59 patients responded to treatment </plain></SENT>
<SENT sid="3" pm="."><plain>In 22 cases complete remission was obtained and in 37 cases partial remission </plain></SENT>
<SENT sid="4" pm="."><plain>The proportion of complete remissions was the same for <z:e sem="disease" ids="C0024302" disease_type="Neoplastic Process" abbrv="">reticulosarcoma</z:e> (9 out of 28) and <z:e sem="disease" ids="C0079734" disease_type="Neoplastic Process" abbrv="">lymphosarcoma</z:e> (7 out of 22) </plain></SENT>
<SENT sid="5" pm="."><plain>The remission rate for <z:e sem="disease" ids="C0024301" disease_type="Neoplastic Process" abbrv="">Brill-Symmers disease</z:e> was higher (6 out of 14) </plain></SENT>
<SENT sid="6" pm="."><plain>For patients with <z:e sem="disease" ids="C0079734" disease_type="Neoplastic Process" abbrv="">lymphosarcoma</z:e> the average duration of complete remission was 26.9 months and for patients with <z:e sem="disease" ids="C0024302" disease_type="Neoplastic Process" abbrv="">reticulosarcoma</z:e> 25 months </plain></SENT>
<SENT sid="7" pm="."><plain>42 of the 59 patients who responded to treatment survived one year, 33 of them two or more years </plain></SENT>
<SENT sid="8" pm="."><plain>After a two-year period there were no more <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
</text></document>